Multiple randomized controlled trials and meta-analyses in patients with type 2 diabetes and obesity demonstrate that GLP-1RA therapy either preserves or modestly increases bone mineral density (BMD) at key skeletal sites lumbar spine and hip, GLP-1RAs also favorably modulate bone turnover markers, increasing bone formation markers (P1NP, osteocalcin, bone-specific alkaline phosphatase) and reducing bone resorption markers (-CTX), suggesting a net positive or neutral effect on bone remodeling
GLP-1s are usually not recommended for people who: Have severe gastrointestinal issues, such as gastroparesis Have an intolerance or allergy to GLP-1s Are pregnant or breastfeeding Have a personal or family history of rare forms of thyroid cancer called medullary thyroid cancer or multiple endocrine neoplasia type 2 Behavioral health is an important consideration before starting GLP-1 medications
Long-term IN delivery induced a sustained, homeostatic metabolic suppression
TERT promoter mutations in familial and sporadic melanoma
More recently, treatment with medical ozone was shown to increase proliferation of human dental pulp stem cells in vitro